可选产品分析
经您允许,我们会使用注重隐私的有限分析来了解哪些研究流程有效。我们不会使用广告跟踪器或会话录制。您可以在偏好设置中更改此选择。请阅读 隐私政策.
argenx SE's published Strong Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $49.9B | |
|---|---|---|
| P/E (forward) | 21.8x |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | Trend |
|---|---|---|---|---|---|
| Period | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $410.7M | $1.23B | $2.19B | $4.15B | +116.2% |
| Gross profit | $381.3M | $1.11B | $1.96B | $3.70B | +113.3% |
| Operating income | $-727.1M | $-303.6M | $87.6M | $1.28B | — |
| Net income | $-709.6M | $-295.1M | $833.0M | $1.29B | — |
| EPS (diluted) | $-13.05 | $-5.16 | $12.78 | $19.57 | — |
| EBITDA | $-622.8M | $-192.3M | $105.2M | $1.31B | — |
| R&D | $663.4M | $859.5M | $983.4M | $1.36B | +27.2% |
| SG&A | $469.9M | $709.5M | $1.05B | $1.36B | +42.5% |
Recent company headlines from major financial publishers.
VYVGART achieves standard-of-care status in 5+ indications simultaneously, driving margins toward 40%+.
Solid execution in gMG and CIDP with steady margin expansion towards the 30% target.
| Ke ↓ / g → | 2.5% | 3.0% | 3.5% | 4.0% | 4.5% |
|---|---|---|---|---|---|
| 6.4% | $1,871 | $2,148 | $2,522 | $2,601 | $2,601 |
| 7.4% | $1,486 | $1,657 | $1,871 | $2,148 | $2,522 |
| 8.4% | $1,233 | $1,348 | $1,486 | $1,657 | $1,871 |
| 9.4% | $1,054 | $1,136 | $1,233 | $1,348 | $1,486 |
| 10.4% | $920 | $982 | $1,054 | $1,136 | $1,233 |
Upcoming earnings date and setup when available.
每月发布的研究版本所给出的评级。评级比较分析日的价格与公允价值,并不记录判断是否正确。
| 年份 | 1月 | 2月 | 3月 | 4月 | 5月 | 6月 | 7月 | 8月 | 9月 | 10月 | 11月 | 12月 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |